Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 9/20 | 0.54 |
| ▸ | GLP1R | P43220 | 1/20 | 0.54 |
| ▸ | GCGR | P47871 | 1/20 | 0.54 |
| ▸ | GIPR | P48546 | 1/20 | 0.54 |
| ▸ | PTH1R | Q03431 | 3/20 | 0.53 |
| ▸ | CD47 | Q08722 | 1/20 | 0.51 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.51 |
| ▸ | GHSR | Q92847 | 3/20 | 0.50 |
| ▸ | NPY2R | P49146 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16692892 | 0.93 | IL23R (0.61) | IL23RGLP1RGCGRGIPRCD47 | |
| SCHEMBL16692898 | 0.93 | IL23R (0.61) | IL23RGLP1RGCGRGIPRCD47 | |
| SCHEMBL19731206 | 0.93 | IL23R (0.61) | IL23RGLP1RGCGRGIPRCD47 | |
| SCHEMBL16692899 | 0.93 | IL23R (0.61) | IL23RGLP1RGCGRGIPRCD47 | |
| SCHEMBL19731216 | 0.93 | IL23R (0.61) | IL23RGLP1RGCGRGIPRCD47 | |
| SCHEMBL24172454 | 0.93 | IL23R (0.61) | IL23RGLP1RGCGRGIPRCD47 | |
| SCHEMBL19731215 | 0.93 | GLP1R (0.61) | IL23RGLP1RGCGRGIPRCD47 | |
| SCHEMBL29973095 | 0.91 | GHSR (0.57) | IL23RGLP1RGCGRGIPRGHSR | |
| SCHEMBL21185972 | 0.90 | IL23R (0.65) | IL23R | |
| SCHEMBL30130542 | 0.88 | IL23R (0.55) | IL23RCD47C5AR1GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759496-B2 | Compounds and pharmaceutical use thereof in the treatment of cancer | Karoyan, Philippe (FR) | 2023-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11759496-B2 | Compounds and pharmaceutical use thereof in the treatment of cancer | VIP, RNASE1, ABCB11 | IL23R 581/4885GLP1R 1060/4885GCGR 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.